Secondary Sclerosing Cholangitis in Critically Ill Patients

Study acronym: SSC-CIP
StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 11 months later Jan 2026 → Jan 2028
See other at-risk trials from Medical University of Graz

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jan 2026 to Jan 2028
    • Study completion pushed from Jan 2028 to Jan 2029
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 1 of 4 entries
  2. Primary completion date: Jan 2025 to Jan 2026
    • Study completion date: Jan 2026 to Jan 2028
    v15
  3. Primary completion date: Jan 2024 to Jan 2025
    • Study completion date: Jan 2025 to Jan 2026
    v14
  4. Re-verified, no change to tracked fieldsv13
  5. Primary completion date: Jan 2022 to Jan 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jan 2022 to Jan 2025
    • Site details revised
    v12
Show 10 earlier versionsHide 10 earlier versions
  1. Re-verified, no change to tracked fieldsv11
  2. Secondary endpoints: 3 to 4v10
  3. Start date: Jul 1, 2018 to Dec 21, 2015v9
  4. Primary completion date: Jan 2020 to Jan 2022
    • Start date: Jan 2015 to Jul 1, 2018
    • Study completion date: Jan 2021 to Jan 2022
    v8
  5. Re-verified, no change to tracked fieldsv7
  6. Primary completion date: Jan 2018 to Jan 2020
    • Study completion date: Jan 2019 to Jan 2021
    v6
  7. 4 versions Re-verified since Oct 2, 2015, no change to tracked fieldsv2-v5
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
SSC-CIP is increasing in patients after critical illness. Pathogenesis is still largely unclear. The investigators hypothesize that genetic variants of biliary transporter genes are frequent in patients with SSC-CIP. In approximately 140 patients and controls the rate of genetic variants in biliary transporter genes, gut permeability and gut microbiome as well as bone health will be studied.
Trial Details
NCT Number NCT02545309
Lead Sponsor Medical University of Graz
Conditions
(from sponsor)		 Secondary Sclerosing Cholangitis
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov